$SPPI (Spectrum Pharmaceuticals, Inc.)

$SPPI {{ '2016-04-20T19:04:45+0000' | timeago}} • Announcement

Biotechnology company $SPPI said the U.S. Food and Drug Administration Office of Orphan Products Development granted 7 years of Orphan Drug Exclusivity for its drug EVOMELA for use as a high-dose conditioning treatment in patients with multiple myeloma.

$CORE {{ '2017-09-21T13:02:10+0000' | timeago}} • Announcement

$CORE, marketers of fresh and broad-line supply solutions to convenience retail industry, has announced that it has renewed its 3-year supply chain agreement with $RAD. Core-Mark is currently providing service to approx 4,500 Rite Aid stores. Finer details of the agreement are under wraps.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$RAD {{ '2017-09-19T15:31:35+0000' | timeago}} • Announcement

Under the amended and restated asset purchase agreement with $RAD, $WBA does not expect the transaction to have a significant impact to its adjusted EPS in FY17. $WBA also expects to realize annual synergies from the transaction of more than $300MM, which are expected to be fully realized within four years of the initial closing of the transaction.

$WBA {{ '2017-09-19T14:19:18+0000' | timeago}} • Announcement

Drugstore chain $WBA, in its fourth attempt, clinched regulatory approval to buy 1,932 stores, 3 distribution centers and related inventory from $RAD for $4.375Bil. The new deal has 250 fewer stores than the earlier deal & is lower than the previous proposal of $5.18Bil. Store purchases would begin in Oct., with completion expected in spring 2018.

$NEOG {{ '2017-09-19T13:40:41+0000' | timeago}} • Announcement

During 1Q18, $NEOG's Animal Safety segment revenue increased 9% YoY, driven by significant growth in its genomics business. Revenues from Worldwide animal genomics business increased 29% from a year earlier. The rise was basically due to increased market share in the global cattle and poultry markets.

$NEOG {{ '2017-09-19T13:39:04+0000' | timeago}} • Announcement

Food safety company $NEOG reported a 20.57% increase in its 1Q18 earnings, driven by a revenue jump of 13.88% in the quarter. Net income rose to $11.91MM, or $0.31 per share from $9.88MM, or $0.26 per share a year earlier. Revenue rose to $95.25MM from $83.64MM a year ago.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$MYL {{ '2017-09-08T21:46:48+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. Pfizer is continuing to work with the FDA to resolve the points raised in the warning letter regarding Pfizer’s manufacturing of the EpiPen products and Mylan will do whatever it can to support this process.

$MYL {{ '2017-09-08T21:46:14+0000' | timeago}} • Announcement

$MYL issued statement on warning letter issued to $PFE's EpiPen auto-injector manufacturing site. The letter was issued in connection with FDA's inspection of Pfizer’s pharmaceutical manufacturing facility located in Brentwood, Missouri, where the EpiPen products are manufactured.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$BMY {{ '2017-09-07T13:34:21+0000' | timeago}} • Announcement

$BMY said a Phase 3 study evaluating Opdivo plus Yervoy in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) met its co-primary endpoint. This demonstrates superior overall survival (OS) compared to sunitinib in intermediate- and poor-risk patients.

$JNJ {{ '2017-09-06T18:27:40+0000' | timeago}} • Announcement

Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of $JNJ, received FDA approval for a new 32 mg tablet for oral suspension for TRACLEER for use in pediatric patients aged three years and older, suffering from high blood pressure in the arteries of the lungs. The medication will be available from 4Q17.

$VRTX {{ '2017-09-06T14:56:39+0000' | timeago}} • Announcement

$VRTX has announced the appointment of Tom Graney as SVP and CFO with effect from Sept 13, 2017.  He will report to EVP and COO Ian Smith.  Graney will be responsible for the development and execution of the financial strategies and operations of Vertex's business plans. He was the CFO and SVP of Finance and Corporate Strategy at $IRWD.

$PFE {{ '2017-08-29T14:05:59+0000' | timeago}} • Announcement

$PFE and $BMY presented investigational Eliquis data for patients with non-valvular atrial fibrillation undergoing cardioversion. The outcomes measured in EMANATE, a Phase 4 clinical trial, were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding and all-cause death.

$UNH {{ '2017-08-29T12:32:31+0000' | timeago}} • Announcement

Optum, part of $UNH, and $ABCO's health care business will combine. The BoD of $ABCO unanimously approved the merger agreement and has recommended that its stockholders adopt the merger agreement. The merger is expected to close by the end of 2017 or in early 2018. The transaction is expected to be neutral to $UNH's EPS in the first year.

Recent Transcripts

NEOG (Neogen Corp.)
Tuesday, September 19 2017 - 3:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
CCXI (ChemoCentryx, Inc.)
Tuesday, August 8 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
CTIC (CTI BioPharma Corp.)
Thursday, August 3 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, August 1 2017 - 9:00pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, July 27 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
VRTX (Vertex Pharmaceuticals Incorporated)
Wednesday, July 26 2017 - 9:15pm
VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
UHS (Universal Health Services Inc.)
Wednesday, July 26 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm

AlphaGraphics you may like